791 related articles for article (PubMed ID: 10882863)
1. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ
Cancer Lett; 2001 Feb; 163(2):191-200. PubMed ID: 11165754
[TBL] [Abstract][Full Text] [Related]
4. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
Klement G; Baruchel S; Rak J; Man S; Clark K; Hicklin DJ; Bohlen P; Kerbel RS
J Clin Invest; 2000 Apr; 105(8):R15-24. PubMed ID: 10772661
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Rosen LS
Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy.
Harmey JH; Bouchier-Hayes D
Bioessays; 2002 Mar; 24(3):280-3. PubMed ID: 11891765
[TBL] [Abstract][Full Text] [Related]
7. Tumour biology: herceptin acts as an anti-angiogenic cocktail.
Izumi Y; Xu L; di Tomaso E; Fukumura D; Jain RK
Nature; 2002 Mar; 416(6878):279-80. PubMed ID: 11907566
[TBL] [Abstract][Full Text] [Related]
8. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
11. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo.
Gu WZ; Tahir SK; Wang YC; Zhang HC; Cherian SP; O'Connor S; Leal JA; Rosenberg SH; Ng SC
Eur J Cancer; 1999 Sep; 35(9):1394-401. PubMed ID: 10658533
[TBL] [Abstract][Full Text] [Related]
12. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
Rak J; Mitsuhashi Y; Bayko L; Filmus J; Shirasawa S; Sasazuki T; Kerbel RS
Cancer Res; 1995 Oct; 55(20):4575-80. PubMed ID: 7553632
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and anti-angiogenesis in neuroblastoma.
Ribatti D; Vacca A; Nico B; De Falco G; Giuseppe Montaldo P; Ponzoni M
Eur J Cancer; 2002 Apr; 38(6):750-7. PubMed ID: 11937307
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
17. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
18. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
19. VEGF antagonists.
Hasan J; Jayson GC
Expert Opin Biol Ther; 2001 Jul; 1(4):703-18. PubMed ID: 11727506
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenesis in cancer therapeutics: the magic bullet.
Oguntade AS; Al-Amodi F; Alrumayh A; Alobaida M; Bwalya M
J Egypt Natl Canc Inst; 2021 Jul; 33(1):15. PubMed ID: 34212275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
